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Abstract
Background: The C - reactive protein (CRP) response is often measured in patients with active tuberculosis (TB) yet
little is known about its relationship to clinical features in TB, or whether responses differ between ethnic groups or
with different Mycobacterium tuberculosis (M.tb) strain types. We report the relationship between baseline serum
CRP prior to treatment and disease characteristics in a metropolitan population with TB resident in a low TB
incidence region.
Methods: People treated for TB at four London, UK sites between 2003 and 2014 were assessed and data collected
on the following characteristics: baseline CRP level; demographics (ethnicity, gender and age); HIV status; site of TB
disease; sputum smear (in pulmonary cases) and culture results. The effect of TB strain-type was also assessed in
culture-positive pulmonary cases using VNTR typing data.
Results: Three thousands two hundred twenty-two patients were included in the analysis of which 72 % had a
baseline CRP at or within 4 weeks prior to starting TB treatment. CRP results were significantly higher in culture
positive cases compared to culture negative cases: median 49 mg/L (16–103 mg/L) vs 19 mg/L (IQR 5–72 mg/L),
p = <0.001. In those with pulmonary disease, smear positive cases had a higher CRP than smear negative cases:
67 mg/L (31–122 mg/L) vs 24 mg/L (7–72 mg/L), p < 0.001. HIV positive cases had higher baseline CRPs than HIV
negative cases: 75 mg/L (26–136 mg/L) vs 37 mg/L (10–88 mg/L), p <0.001. Differing sites of disease were
associated with differences in baseline CRP: locations that might be expected to have a high mycobacterial load
(e.g. pulmonary disease and disseminated disease) had a significantly higher CRP than those such as skin, lymph
node or CNS disease, where the mycobacterial load is typically low in HIV negative subjects. In a multivariable
log-scale linear regression model adjusting for host characteristics and M.tb strain type, infection with the East
African Indian strain was associated with significantly lower baseline-CRP (fold-change in CRP 0.51 (0.34–0.77), p < 0.01).
Conclusions: Host and mycobacterial factors are strongly associated with baseline CRP response in tuberculosis. This
analysis suggests that there are important differences in innate immune response according to ethnicity, Mtb strain
type and site of disease. This may reflect differing mycobacterial loads or host immune responses.
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Background
The serum C-reactive protein (CRP) concentration is
commonly measured during the investigation or treat-
ment of active Tuberculosis (TB) [1]. Relatively little is
known about how different disease states (e.g. site of dis-
ease), host factors (age, gender, and ethnicity) or myco-
bacterial characteristics (strain type) might influence
CRP values. Furthermore, as the CRP can be taken as an
indicator of the acute innate immune response, such
data may offer clues to the differences in this response
according to host and mycobacterial characteristics.
CRP acts as part of the innate immune response by
binding to ligands such as phosphocholine on dead or
dying cells and bacteria, activating complement C1q and
the classical complement pathway and promoting
phagocytosis. It is primarily produced in the liver (al-
though some tissue production occurs) in response to Il-
6, (plus Il-1β and TNFα) secretion, the major source of
which is macrophages. It is genetically ancient and
highly conserved [2]. Its relatively short half-life (around
19 hours) means that serum CRP levels reflect the rate
of production and can therefore act as a biomarker of
disease activity.
Several studies have evaluated the utility of CRP test-
ing in TB, demonstrating a lower median CRP in TB
compared to bacterial pneumonia [3] and that the
addition of CRP testing to clinical assessment can aid
the management of HIV positive patients in a high TB
incidence setting [4–6]. Furthermore high baseline CRP
levels have been shown to correlate with slow sputum
culture conversion [7] and with poor treatment out-
comes;[8] and a raised CRP after 8 weeks of TB treat-
ment has been found to be predictive of continued
culture-positive status[9]. Different TB strain-types are
believed to have co-evolved with different human popu-
lations [10], and mycobacteria from different M.tb line-
ages can provoke different inflammatory responses in
human macrophages in-vitro [11]. In addition, differ-
ences in inflammatory responses in active Tuberculosis
have been reported in different ethnic groups [12].
The extent to which these possible effects impact on
measurements of inflammatory response seen in clinical
practice is not known, as the distribution of CRP results
in active TB, and how clinical parameters may affect this
has not been explored in a large patient group. We
therefore investigated a cohort of individuals being
treated for active TB and examined the association be-
tween the baseline CRP results and host and mycobac-
terial characteristics.
Methods
We undertook a retrospective study of a cohort of pa-
tients treated for active TB between 2003 and 2014 in
four hospitals in London, UK - a setting with an
incidence of TB of around 35–40 cases/100,000 pa dur-
ing the study period [13]. Active TB was defined as any
patient treated for TB. CRP results at the time of, or
within 4 weeks prior to, TB treatment initiation were ob-
tained from hospital electronic patient records. These
were measured by the clinical biochemistry laboratories
in the treating hospitals, using standard immuno-
turbidimetric assays. The normal range for the CRP at
all sites was 0–5 mg/L; there were no differences in this
according to subject age, ethnicity or gender. Some la-
boratories did not report exact values for CRP results
within the normal range (instead giving the result as be-
ing below 5 mg/L) in these cases a value of 4 mg/L was
used in the analysis.
Data were collected from existing hospital databases
and electronic patient records, supplemented where ne-
cessary by information from the London TB Register, an
electronic database which forms part of Public Health
England’s Enhanced TB surveillance system. We ob-
tained information on the following parameters: baseline
CRP (when, or within four weeks before, starting treat-
ment); patient characteristics (age, gender and ethnicity);
site of disease; smear and culture results. We also col-
lected data on M.tb strain-type for a subgroup of isolates
from patients with pulmonary TB.
Data were analysed in Excel (Microsoft) and SPSS
(IBM). Descriptive statistics of characteristics associated
with baseline CRP were calculated. Multivariable linear
regression models were built, using the log-CRP (which
approximated a normal distribution). As well as a sub-
group analysis evaluating the effect of M.tb strain type,
sensitivity analyses were undertaken using only culture-
confirmed TB cases and with alternative coding using
place of birth as a proxy for ethnicity.
Results
Data regarding 3,222 patients treated for active TB were
obtained. Of these, 2307 (72 %) had a CRP result which
we could include in the analysis. Patients were more
likely to have a CRP measured if they had culture posi-
tive disease compared to culture negative (74 % with a
CRP result vs 65 %, p <0.001), HIV positive compared to
HIV negative (81 vs 77 %, p < 0.001) and if they were
male (67 vs 63 %, p = 0.035) (Additional file 1: Table S1).
The CRP was less likely to be measured in those of
White ethnicity compared to other ethnic groups (59 vs
72 %, p <0.001) or who had disease at peripheral lymph
node or CNS sites (62 and 66 % respectively, compared
to 71–90 % at other disease sites (p <0.001).
Characteristics of the patients included in the analysis
are presented in Table 1. The median age was 37 years
(IQR 25–47 years), 55 % had pulmonary disease, 67 %
were culture positive and 10 % HIV co-infected. For the
whole cohort, the median CRP was 40 mg/L (IQR 11–
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94 mg/L) with a strongly positively skewed distribution.
Thirteen percent of the whole cohort and 9 % of those with
culture-confirmed disease had a baseline CRp <5 mg/L.
Disease and patient characteristics were highly associ-
ated with baseline CRP (Table 2). The CRP was greater
in patients with culture positive disease compared to
culture negative (49 mg/L vs 19 mg/L p < 0.001). In
those with pulmonary disease, smear positive cases had
higher CRPs than smear negative subjects (66 mg/L vs
28 mg/L p < 0.001). Men had higher baseline CRPs than
women (51 mg/L vs 32 mg/L p < 0.001) and adults had
higher CRPs than children. Significant differences were
noted at certain sites of disease, such that pulmonary
(median CRP 47 mg/L), pleural or pericardial (84 mg/L)
or abdominal (65 mg/L) had higher CRPs than peripheral
lymph node (14 mg/L), skin and soft tissue (11 mg/L) or
CNS disease (13 mg/L) (Fig. 1). Ethnicity appeared also to
influence baseline CRP, with lower values found in those
of Asian ethnicity, who had a median CRP of 20 mg/L
(Fig. 2).
Many of the characteristics related to baseline CRP
were strongly correlated with each other, thus confound-
ing the apparent associations in this univariable analysis,
(for instance, pulmonary disease was significantly less
common, and peripheral lymph node disease more com-
mon, in those with Asian ethnicity). We therefore com-
pleted a multivariable analysis (using the log-CRP for
linear regression) (Table 3). Here, TB culture status, site
of disease and gender remained significantly associated
with higher baseline CRP result. Asian ethnicity was
Table 1 Cohort characteristics
Total cohort (N = 3,222) N (%)
Age, years <16 243 (7.6 %)
16–34 1482 (46.4 %)
35–50 831 (26 %)
50+ 635 (19.9)
Gender male Male 1466 (57.5 %)
Female 1078 (42.3 %)
Ethnicity code White 616 (23.0 %)
Black African/Caribbean 977 (36.5 %)
Asian 641 (23.9 %)
Eastern Mediterranean
and North Africa
297 (11.1 %)
Americas 148 (5.5 %)
Site of disease Pulmonary or mediastinal
lymph node
1780 (55.2 %)
Pleural or pericardial 233 (7.2 %)
Abdominal 119 (3.7 %)
Miliary/disseminated 75 (2.3 %)
Bone and joint 197 (6.1 %)
Peripheral lymph node 533 (16.5 %)
Skin and soft tissue 31 (1.0 %)
CNS 126 (3.9 %)
Other/unknown 128 (4.0 %)
Culture status Culture negative 1027 (32.5 %)
Culture positive 2136 (67.5 %)
Smear status
(pulmonary cases)
Smear negative 598 (54.7 %)
Smear positive 495 (45.3 %)
HIV Status HIV positive 333 (10.3 %)
HIV negative 2020 (62.8 %)
HIV status unknown 865 (26.9 %)
Table 2 Association of clinical parameters with baseline CRP
value
Baseline CRP
Median (IQR)
Age category Age <16 16 (4–48) p < 0.001*
Age 16–35 40 (11–93)
Age 35–50 50 (14–107)
Age >50 39 (13–98)
Gender male Male 51 (15–109) p < 0.001**
Female 32 (11–78)
Ethnicity White 50 (16–107) p < 0.001*
Black African/
Caribbean
49 (16–103)
Asian 20 (7–54)
Eastern Mediterranean
and North Africa
51 (17–112)
Americas 65 (28–109)
HIV status HIV negative 37 (10–88) p < 0.001*
HIV positive 75 (26–136)
HIV status unknown 35 (11–86)
Smear status Smear negative 28 (7–74) p < 0.001**
Smear positive 66 (30–121)
Culture result Culture negative 19 (5–72) p < 0.001**
culture positive 49 (16–103)
Site of disease Pulmonary or
mediastinal lymph
node
47 (14–100) p < 0.001*
Pleural or pericardial 84 (36–132)
Abdominal 65 (29–124)
Miliary/disseminated 61 (26–125)
Bone and joint 33 (10–78)
Peripheral lymph
node
14 (4–41)
Skin and soft tissue 11 (1–61)
CNS 13 (4–31)
Other./unknown 33 (12–76)
*Kruskall Wallis
**Mann Whitney U Test
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significantly associated also with a lower baseline CRP
compared to other ethnic groups (Asian ethnicity, ad-
justed fold-change in CRP 0.49 (95 % CI 0.40–0.58)
compared to Black ethnicity).
Differences in M.tb strain type have been associated with
differing clinical characteristics. For example, the Beijing
strain was found in some analyses to relate to increased
virulence and acquisition of drug resistance [14, 15]. We
therefore sought to test the hypothesis that strain type
could be affecting baseline CRP response within our
dataset. This was performed in a subgroup of patients for
whom data on strain-typing by VNTR were available (rou-
tinely conducted since 2010) and undertaken only in cases
with pulmonary disease to allow for the strong effect of
disease site on baseline CRP and the relatively small num-
bers with culture-confirmed disease for whom strain-type
data might be available at other body sites.
Four hundred and three cases with culture-confirmed
pulmonary disease had both strain-type and baseline
CRP available, and were included in this analysis. Similar
Fig. 1 Association between sites of disease and median baseline CRP
Fig. 2 Association between ethnicity and baseline CRP
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Table 3 Log-scale linear regression model of effect of disease parameters on baseline CRP in active Tuberculosis
Fold-change in CRP, univariable analysis Fold-change in CRP, multivariable analysis
TB culture result Negative 0.52 (0.46–0.58) p <0.001 0.55 (0.47–0.64) p < 0.001
Positive Reference
Ethnicity White 0.97 (0.83–1.14) p = 0.737 0.87 (0.81–1.04) p = 0.139
Americas 1.37 (1.05–1.80) p = 0.022 1.22 (0.89–1.67) p = 0.213
Asian 0.51 (0.44–0.60) p <0.001 0.49 (0.40–0.58) p < 0.001
Eastern Mediterranean 1.04 (0.86–1.26) p = 0.7 1.06 (0.85–1.31) p = 0.570
Black Reference
HIV status Positive 1.77 (1.49–2.10) p < 0.001 1.37 (1.13–1.67) p = 0.001
Negative Reference
Age <16 0.48 (0.37–0.62) p < 0.001 0.68 (0.46–0.99) p = 0.044
16–35 0.94 (0.82–1.09) p = 0.427 0.86 (0.70–1.03) p = 0.104
35–50 1.08 (0.92–1.27) p = 0.351 0.88 (0.72–1.08) p = 0.223
<50 Reference
Site of disease Pleural/pericardial 1.70 (1.40–2.06) p < 0.001 1.49 (1.17–1.88) p = 0.01
Abdominal 1.56 (1.19–2.06) p = 0.001 1.77 (1.29–2.42) p <0.001
Miliary/disseminated 1.46 (1.07–2.00) p = 0.018 1.24 (0.86–1.79) p = 0.243
Bone/joint 0.84 (0.68–1.04) p = 0.111 0.92 (0.71–1.19) p = 0.540
Peripheral lymph node 0.44 (0.38–0.52) p < 0.001 0.52 (0.42–0.63) p <0.001
Skin/soft tissue 0.29 (0.18–0.48) p < 0.001 0.41 (0.23–0.70) p = 0.001
CNS 0.41 (0.31–0.55) p < 0.001 0.38 (0.28–0.53) p < 0.001
Pulmonary Reference
Gender Male 1.40 (1.24–1.58) p <0.001 1.29 (1.13–1.48) p <0.001
Female Reference
Fig. 3 Distribution of different of Mycobacterium tuberculosis (M.tb) strain types according to host ethnicity in patients with culture-positive
pulmonary tuberculosis
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relationships between gender, HIV status, ethnicity and
age were present in this subgroup as in the full dataset,
albeit with lower power to detect differences given the
smaller sample size. Unadjusted analyses suggested
lower baseline CRPs for those with East African Indian
(EAI) or Central Asian Strain (CAS) type compared to
Euro-American (the dominant strain in this population
representing 55 % of isolates) or Beijing strains. It should
be noted that those of Asian ethnicity were more likely
to have an infection with isolates of CAS or EAI strain
types (Fig. 3), which tended to be associated with lower
CRPs. The apparent association between Asian ethnicity
and lower baseline CRP was therefore significantly atten-
uated in the fully adjusted multivariable model which in-
cluded strain type, where those of Asian ethnicity had a
lower baseline CRP than those of Black ethnicity (the
reference category in this analysis): adjusted fold-change
in baseline CRP 0.72 (0.53–0.99) (Table 4). White ethni-
city was also associated with lower CRPs than Black eth-
nicity: fold-change 0.71 (0.53–0.95) p = 0.020. Strain-type
was associated with baseline CRP, although a statistically
significant difference was only found with isolates of EAI
strain type, where a 0.49 (0.33–0.73, p = 0.001) fold
lower adjusted baseline CRP was seen compared to
those of Euro-American strains.
Sensitivity analyses were undertaken using different
coding strategies. The data on ethnicity depended on
that recorded by the treating clinicians (which might be
incorrect); using place of birth as a proxy for ethnicity
and dividing this into WHO regions (to give 6 categor-
ies) resulted in very similar findings, with lower CRPs in
those of Southeast Asian and Western Pacific regions in
unadjusted analyses. Our full dataset included any pa-
tient treated for TB, to allow analysis of culture negative
cases. Repeating the analysis with only culture positive
cases demonstrated similar associations between the
other examined clinical parameters.
Discussion
This analysis of a large cohort of patients treated for ac-
tive TB in a low-TB incidence, resource-rich setting
demonstrates that the baseline CRP differs considerably
with host and disease characteristics. We found signifi-
cantly lower median CRP results in patients with disease
at sites typically associated with low mycobacterial load
such as peripheral lymph node or CNS disease [16, 17].
CRP was also lower in HIV negative compared to HIV
positive people [18], and culture negative compared to
culture positive cases. One hypothesis that would ac-
count for these associations is that CRP could reflect
mycobacterial load, although we note that pleural and
pericardial disease (which are also thought to be pauci-
bacillary) also had high baseline CRPs, which in these
cases may reflect a more inflammatory immune
response.
We found an apparent association between Asian eth-
nicity and a lower median baseline pre-treatment CRP.
However when we adjusted for site of disease and M.tb
strain type, using an analysis restricted to culture posi-
tive pulmonary cases, this association was weakened,
suggesting that this may be partially explained by infec-
tion with either EIA or CAS strains predominating in
Asian patients. However, differences in illness behaviours
and barriers to access of care between ethnic groups
could also act as a confounding factor which could influ-
ence baseline CRPs in our cohort.
The serum CRP is well established as a clinically useful
biomarker in other conditions - for instance it has been
shown to predict outcome and have a role in guiding
therapy in community acquired pneumonia [19, 20]. If
Table 4 Effect of Mycobacterium tuberculosis (M.tb) strain type and host ethnicity in patients with culture-positive pulmonary
tuberculosis
Parameter Unadjusted baseline
CRP median(IQR) mg/L
Fold change in CRP,
multivariable (log-scale) linear regression model*
M.tb strain type Beijing 62 (17–82) 0.93 (0.55–1.55) p = 0.772
East African-Indian 29 (14–70) 0.49 (0.33–0.73) p = 0.001
Central Asian Strain 28 (14–84) 0.71 (0.50–1.00) p = 0.053
Unassigned 56 (28–115) 0.97 (0.68–1.38) p = 0.871
Euro-American 70 (30–124) Reference
Ethnicity Americas 59 (22–82) 0.73 (0.37–1.43) p = 0.357
Asian 30 (15–75) 0.72 (0.53–0.99) p = 0.045
Eastern Mediterranean 73 (40–118) 1.33 (0.81–2.19) p = 0.260
White 57 (19–113) 0.71 (0.53–0.95) p = 0.020
Black 73 (28–128) Reference
*Adjusted for age, gender and HIV status as well the parameters in the table
Factors significant at 0.05 significance level highlighted in bold
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serum CRP reflects TB mycobacterial load then this
would support its use as part of clinical evaluation in
active TB. For example, a high baseline CRP might sug-
gest that longer treatment duration is necessary (import-
antly, a high baseline CRP appears to be associated with
an increased likelihood of death in active TB [8])
Equally, the failure of CRP to normalise with treatment
may indicate that therapy is less effective than it should
be (e.g. due to drug failure or poor adherence) - trigger-
ing increased clinical input and re-assessment. This
study has evaluated CRP as a blood biomarker, however
evaluation of CRP levels in other specimens, such as sal-
iva may also be of value [21] or of other inflammatory
biomarkers which might be detectable in urine (which
could perhaps be evaluated as point-of-care tests in the
future [22]).
Limitations of this study include its retrospective de-
sign and the use of routinely collected clinical data. Con-
sequently, only 72 % of patients had a baseline CRP
result, and there were significant differences between
those with and without a CRP. Given that people in
whom the CRP was not measured were more likely to
have disease at sites associated here with a low CRP, and
less likely to have HIV coinfection, we may have over-
estimated the true CRP values for the active TB popula-
tion as a whole and under-estimated the proportion with
a normal CRP level. In addition, differences in the pro-
portion of individuals with a CRP result according to
host characteristics (for instance White individuals were
less likely to have a CRP measurement) could be a
source of bias for our findings. The retrospective design
and limited information regarding disease severity mean
that we cannot determine if the differences in baseline
CRP response seen with M.tb strain type results from
greater mycobacterial load being associated with, or result-
ing from, a particular M.tb strain, or if the strain type itself
leads to a different immune response in terms of magni-
tude or quality to a given number of mycobacteria.
Different bacterial strain types are known to have im-
portant effects on clinical presentation and outcomes in
other infections, such as Streptococcus pneumoniae. [23]
It is less clear whether or not significant differences exist
between strain types of Mtb although it has been sug-
gested that the Beijing strain is more virulent or more
likely to acquire drug resistance [24]. Our data cannot
assess this, although encourage further work in this area.
Conclusions
This study demonstrates that baseline CRP reflects im-
portant clinical parameters in patients with active TB
and confirms that variation in this immune response oc-
curs with different TB strain-types after adjustment for
disease and host characteristics. As well as aiding the
interpretation of such baseline CRP results in clinical
practice, this lends support to the use of this test as a
marker of disease severity in TB.
Additional file
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